## **Special Issue**

# The Role of Na,K-ATPase in Human Health: From Structure to Function

#### Message from the Guest Editors

The transport and receptor functions of the enzyme are sensitive to oxygen concentrations and the redox status of the cell, and one of the key determinants of the enzyme's redox sensitivity is S-glutathionylation of the Na,K-ATPase subunits. Dysregulation of Na,K-ATPase functioning has an important impact on numerous human pathological conditions including cancer; chronic kidney disease; preeclampsia; and cardiovascular, metabolic and neurological disorders. Na.K-ATPase is also of great interest in viral biology because it is a prominent therapeutic target in a broad spectrum of viral infections. Understanding the molecular mechanisms of Na,K-ATPase dysfunction in pathologies will allow us to propose new methods for the prevention or correction of these diseases in the future. This Special Issue welcomes original articles and reviews on the role of Na,K-ATPase in the pathogenesis of various human disorders and the molecular mechanisms underlying Na,K-ATPase dysfunction.

#### **Guest Editors**

Dr. Elizaveta Klimanova

Prof. Dr. Olga Lopina

Dr. Irina Petrushanko

#### Deadline for manuscript submissions

closed (31 December 2022)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/112247

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





### **About the Journal**

#### Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).